Myocardial blood flow (MBF) and flow reserve are usually quantified in the clinic with positron emission tomography (PET) using a perfusion-specific radiotracer (e.g.Rb-chloride). However, the clinical accessibility of existing perfusion tracers remains limited. Meanwhile,F-fluorodeoxyglucose (FDG) is a commonly used radiotracer for PET metabolic imaging without similar limitations. In this paper, we explore the potential ofF-FDG for myocardial perfusion imaging by comparing the myocardial FDG delivery ratewith MBF as determined by dynamicRb PET in fourteen human subjects with heart disease. Two sets of FDGwere derived from one-hour dynamic FDG scans. One was the original FDGestimates and the other was the correspondingvalues that were linearly normalized for blood glucose levels. A generalized Renkin-Crone model was used to fit FDGwith Rb MBF, which then allowed for a nonlinear extraction fraction correction for converting FDGto MBF. The linear correlation between FDG-derived MBF and Rb MBF was moderate (= 0.79) before the glucose normalization and became much improved (> 0.9) after glucose normalization. The extraction fraction of FDG was also similar to that of Rb-chloride in the myocardium. The results from this pilot study suggest that dynamic cardiac FDG-PET with tracer kinetic modeling has the potential to provide MBF in addition to its conventional use for metabolic imaging.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1361-6560/ac15a6 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!